Conference Description:

Advance More Personalized Therapies for Rare and Common Kidney Diseases
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of promising new targets in development, has truly lit the fuse on decades of innovative kidney research.

Bringing together 200+ biopharma stakeholders, from scientific research to clinical development and outcomes, across three days of concentrated discussion, the 6th CKD Drug Development Summit is the definitive forum for KOLs, industry experts, and regulators to concentrate kidney innovation onto the next generation of drug development.

From uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm, join Novo Nordisk, Boehringer Ingelheim, Eli Lilly, AstraZeneca, the FDA, Regeneron, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.



URL:
Tickets: https://go.evvnt.com/2060099-2?pid=154
Time: 8:00 AM - 5:00 PM

Prices:
Drug Developer - Conference Only: USD 2999.00,
Drug Developer - Conference + Pre-Conference Seminar Day: USD 4946.00,
Drug Developer - Conference + Pre-Conference Workshop Day: USD 4946.00,
Vendor - Conference Only: USD 3699.00,
Vendor - Conference + Pre-Conference Seminar Day: USD 5846.00,
Vendor - Conference + Pre-Conference Workshop Day: USD 5846.00

Speakers: Achim Obergfell, Global Medical Head Nephrology, CSL Vifor, Aliza Thompson, Deputy Director, Division of Cardiology and Nephrology, FDA, Amit Sharma, Vice President Clinical Development - Global Therapeutic Area Head Nephrology and Hematology, Alexion Pharmaceuticals, Anil Karihaloo, Senior Principal Research Scientist, Novo Nordisk, Ankit Patel, Associate Medical Director, Vertex Pharmaceuticals, Asim Dey, Senior Advisor, Diabetic Complication Therapeutic Area, Eli Lilly, Astrid Weins, Assistant Professor of Pathology, Brigham and Women’s Hospital, Bhupinder Singh, Chief Medical Officer, Renibus Therapeutics, Bonnie Schneider, Co-founder and Director, IGA Nephropathy Foundation, Carol Quinn, Nephrology Global Medical Science Leader, Roche, Carolina Aldworth, Senior Medical Director, Novartis, Charles Lee, Executive Director, Regulatory Affairs, Cardiovascular, Renal and Metabolism, AstraZeneca, Denis Feliers, Director/ARF, Pfizer, Dominik Steubl, Senior Leader - Clinical Program, Boehringer Ingelheim, Doug Paul, Board Member, NephKey, Edgar Jaimes, Professor of Medicine, Weill Cornell Medical College, Fady Botros, Associate Vice President, Eli Lilly, Federica Genovese, Director, Cardiovascular and Renal Research, Nordic Bioscience, Fredrik Erlandsson, Chief Medical Officer, Purespring Therapeutics, Giorgia Snijder, Head of Therapeutic Research Nephrology, CSL Vifor, Hans-Joachim Anders, Professor of Nephrology, University of Munich, Hiddo Heerspink, Professor, University of Gronigan, Houston Gilbert, Vice President, Biometrics, HI-Bio, Jay Elliott, Executive Director, Medical Strategy, Otsuka, Jeffrey Hafkin, Senior Director, Otsuka, Jerome Rossert, Vice President, Head of Clinical Renal, AstraZeneca, Jiahua Li, Senior Medical Director, Alpine Immune Sciences, Jonathan Barratt, The Mayer Professor of Renal Medicine, University of Leicester, Katherine Garlo, Director, Global Medical Sciences, Alexion, Kelly Helm, Executive Director of Patient Engagement, NephCure, Kerry Cooper, Head of Medical Affairs, Vera Therapeutics, Kirtida Mistry, Senior Physician and Clinical Reviewer, Division of Cardiology and Nephrology, FDA, Krzysztof Kiryluk, Associate Professor of Medicine, Division of Nephrology, Department of Medicine, Columbia University, Lauren Eva, Executive Vice President, Professional Relations, NephCure, Lynne Yao, Director, Division of Pediatrics and Maternal Health, FDA, Maarten Hoek, Vice President and Head of Biology, Maze Therapeutics, Maria Ali, Chief Medical Officer, George Clinical, Mary Haas, Manager, Cardiovascular Metabolic and Skeletal Disease Genetics, Regeneron Genetics Centre, Matthias Kretzler, Professor of Internal Medicine and Bioinformatics, University of Michigan, Meike Brinker, Global Clinical Leader, Bayer, MK Farmer, Clinical Development Lead, Takeda, Mohit Mathur, Director, Clinical Development, Visterra, Nikhil Agrawal, Global Development Medical Director, AstraZeneca, Ogo Egbuna, Vice President - Clinical Development, Vertex Pharmaceuticals, Pablo Cabral, Senior Director, External Innovation, Eli Lilly, Patrick Schloemer, Principal Statistician, Bayer, Phil McEwan, Chief Executive Officer, Health Economics and Outcomes Research Ltd, Richard Philipson, Chief Medical Officer, Calliditas Therapeutics, Roberto Pecoits-Filho, Scientific Leader, The George Institute, Romer Gonzalez-Villalobos, Scientific Director, Kidney Diseases, Janssen, Samvel Gasparyan, Statistical Science Associate Director, AstraZeneca, Simone Sanna-Cherchi, Associate Professor, Columbia University, Sorin Fedeles, Executive Director, Polycystic Kidney Disease Outcomes Consortium, C-Path, Stephen Elliman, Chief Scientific Officer, Orbsen Therapeutics, Steve Olson, Senior Medical Director; Renal, Novartis, Suhail Tahir, Senior Scientist, Sanofi, Thomas Hiemstra, Senior Director, Clinical Development, GSK, Thomas Idorn, International Medical Vice President, Novo Nordisk, Thorsten Vetter, Senior Scientific Officer, EMA, Tobias Agervald, Chief Executive Officer, Guard Therapeutics, Tom Greene, Professor of the Division of Biostatistics, Department of Population Health Sciences, University of Utah, Ulf Meier-Kriesche, Chief Scientific Officer, Veloxis Pharmaceuticals, Vishal Duggal, Associate Medical Director, Genentech